Progress for our clients in the clinic this week, with Mestag Therapeutics dosing the first patient in their STARLYS clinical trial and STORM Therapeutics to present data on its dose escalation study at ASCO later this month. More good news, as Hansa Biopharma entered a multi-million-Euro licensing agreement with SERB S.A. Bring on the bank […]
SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]
Ottimo Pharma, a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, on Thursday announced the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and […]
Congratulations to Renée Aguiar-Lucander, who won the prestigious Executive of the Year Award – Commercial Stage Companies at the Scrip Awards 2024 As the awards celebrated their 20th anniversary, Renée came top from a list of finalists representing the very best in the biotech industry. Renée led the company through clinical development of Tarpeyo (budesonide), […]
